Klinikum der Universität München-Großhadern

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Aortic stenosis1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Kidney cancer1 trial
• Prostate cancer1 trial
• Sarcoma1 trial
• Stroke1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting3 trials
• Recruiting2 trials

Lead sponsor

• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest3 trials
• AstraZeneca1 trial
• Edwards Lifesciences1 trial
• Eli Lilly and Company1 trial
• IHF GmbH - Institut für Herzinfarktforschung1 trial
• and 2 more

Running trials

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  NCT06320067· Phase 3· University College, London· Source

• Active, not recruiting

  Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

  NCT05043090· Phase 3· AstraZeneca· Source

• Active, not recruiting

  TRISCEND II Pivotal Trial

  NCT04482062· Edwards Lifesciences· Source

• Active, not recruiting

  accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis

  NCT03863132· IHF GmbH - Institut für Herzinfarktforschung· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

  NCT03530267· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Eli Lilly and Company· Source